Compare Davita Inc (DVA) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Under Armour Inc Class A — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Under Armour Inc Class A trades at $4.74 (market cap $2.05B). The key difference: Davita Inc is far larger — about 5.5× Under Armour Inc Class A's market cap, and Davita Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Under Armour Inc Class A for 18 Days on average.
| DVA | UA | |
|---|---|---|
Market Cap | $11.28B | $2.05B |
Volume | 650,294 | 3,002,780 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $7.88 |
52-Week Low | $103.87 | $3.96 |
Typical Hold Time | 113 Days | 18 Days |
Enterprise Value | $24.00B | $3.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Under Armour (UA) trades at $4.70, down 0.42% with a bearish technical outlook despite recent earnings beats. The company faces significant challenges with negative net income margins (-9.99%) and declining revenue trends, though it maintains a reasonable P/S ratio of 0.41. Recent quarterly results show mixed performance with two beats and one miss, while cash flow remains negative across all categories.
The stock presents high risk with deteriorating fundamentals and negative profitability metrics. While analyst sentiment leans slightly positive with 41% buy ratings, the company's revenue declines and negative cash flow position create substantial headwinds. Investment opportunity exists only for those betting on a successful turnaround strategy execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
